11.46
-0.02(-0.17%)
Currency In USD
| Previous Close | 11.48 |
| Open | 11.47 |
| Day High | 11.53 |
| Day Low | 11.17 |
| 52-Week High | 42.79 |
| 52-Week Low | 10.69 |
| Volume | 48,647 |
| Average Volume | 79,016 |
| Market Cap | 77.72M |
| PE | -1.01 |
| EPS | -11.35 |
| Moving Average 50 Days | 14.38 |
| Moving Average 200 Days | 20.49 |
| Change | -0.02 |
If you invested $1000 in Instil Bio, Inc. (TIL) since IPO date, it would be worth $21.67 as of December 25, 2025 at a share price of $11.46. Whereas If you bought $1000 worth of Instil Bio, Inc. (TIL) shares 3 years ago, it would be worth $1,193.75 as of December 25, 2025 at a share price of $11.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
GlobeNewswire Inc.
Sep 10, 2025 11:00 AM GMT
ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC for PD-(L)1xVEGF bispecifics DALLAS, Sept. 10, 2
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
GlobeNewswire Inc.
Jul 31, 2025 10:00 AM GMT
Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting toxicities observed in patients with front-line N
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
GlobeNewswire Inc.
Jul 02, 2025 10:00 AM GMT
US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE N